HALEY PEMBERTON: Open Payments
NPI 1770268138 · WETUMPKA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,209 in 110 payments from 24 companies in 2025. Trend: 2023 $300 · 2024 $1,377 · 2025 $2,209
Food & beverage: $2,209
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $375 |
| Neurocrine BioSciences, Inc. | 13 | $312 |
| PFIZER INC. | 9 | $175 |
| AstraZeneca Pharmaceuticals LP | 7 | $169 |
| Otsuka America Pharmaceutical, Inc. | 8 | $159 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $109 |
| GlaxoSmithKline, LLC. | 5 | $97 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $97 |
| Lundbeck LLC | 4 | $90 |
| Axsome Therapeutics, Inc. | 4 | $77 |
Products named: INGREZZA, REXULTI, Rybelsus, AIRSUPRA, Ozempic, TRELEGY ELLIPTA, Kerendia, ELIQUIS.
Industry payments across AL — which companies pay providers there.
